Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries

Linde, Louise;Ørnbjerg, Lykke M;Georgiadis, Stylianos;Rasmussen, Simon H;Lindström, Ulf;Askling, Johan;Michelsen, Brigitte;Di Giuseppe, Daniela;Wallman, Johan K;Gudbjornsson, Bjorn;Love, Thorvardur Jon;Nordström, Dan C;Yli-Kerttula, Timo;Nekvindová, Lucie;Vencovský, Jiří;Iannone, Florenzo;Cauli, Alberto

Investigation

;Loft, Anne Gitte;Glintborg, Bente;Laas, Karin;Rotar, Ziga;Tomšič, Matija;Macfarlane, Gary J;Möller, Burkhard;van de Sande, Marleen;Codreanu, Catalin;Nissen, Michael J;Birlik, Merih;Erten, Sukran;Santos, Maria J;Vieira-Sousa, Elsa;Hetland, Merete L;Østergaard, Mikkel

2023-01-01

---

Abstract

Objectives: In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes, were defined as common predictors. Results: In the pooled cohort (n = 13 369), six-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6,954, n = 5,275 and n = 13 369, respectively). Baseline predictors of remission, moderate response and 12-month drug retention were identified, five common across all three outcomes. Odds ratios (95% confidence interval) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (< 2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP >10 vs ≤ 10 mg/l: 1.52 (1.22-1.89) and one mm increase in patient fatigue score: 0.99 (0.98-0.99). Conclusion: Baseline predictors of remission, response and adherence to TNFi were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalisable from the country- to disease-level.